Zogenix, Inc.

Good day and welcome to the Zogenics, Inc. Second Quarter 2021 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie, LifeSci Advisors. Please go ahead.

Thank you, Operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Dr. Stephen Farr, Chief Commercial Officer, Ashish Sigurlicar, and Chief Financial Officer, Michael Smith. This afternoon, Zigenix issued a news release providing a business update and announcing financial results for the three and six months ended June 30, 2021. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Zigenix management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Zorgenix's press release issued today and the company's SEC filings, including in the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast August 5th, 2021. Legenics undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now, I'd like to turn the call over to Steve.

Thank you, Brian, and good afternoon to everyone. I'm delighted to be here with you today to provide updates on what continues to be an exciting and productive period for Zygenix as we further ramp commercial activities for Pintepa Interbay Syndrome and advance our development programs for Pintepa and other areas of our pipeline that I will update you on later during today's call. First, I'd like to provide a brief update on our commercialization of Pintepa. We continue to achieve significant progress around the launches of Pentecla for Dravet syndrome in the United States and Europe, where we see continued meaningful quarter-over-quarter growth in the number of prescribers, patients on Pentecla, as well as net sales revenue. Pentecla addresses the large unmet needs of the Dravet community by enabling more patients to achieve significant and lasting seizure reduction. With physician interest remaining strong, we expect these positive trends to continue. As expected from our previous clinical trial experience, patient adherence to teplotherapy continues to be very high and discontinuation is low. Our first annual report submitted to the FDA confirmed that the fintepra rest process is working exceptionally well and that REBA echo monitoring continues to show no evidence of other heart disease or pulmonary arterial hypertension in any patient taking fintepra. During the second quarter, as COVID restrictions began to lift in many parts of the U.S., our field-based teams had more face-to-face physician visits than at any time since launch, leading to more physicians and their staff educated about the benefits of Pentapla and the REMS process. To this end, June represented the highest monthly number of new patients referred to the REMS program. This success in commercializing our first rare disease therapy, coupled with active preparations for our next phase of growth, has led to more complex demands on our business. I'm pleased, therefore, to announce the promotion of Ashish Sarkarika to Executive Vice President and Chief Operating Officer. Ashish has been a critically valuable member of our executive team and has established and grown our commercial teams for the launch of Futapla in the United States and in Europe. In this newly creative role, he'll be responsible for leading the company's commercial growth trajectory and global commercial strategic planning, as well as overseeing pharmaceutical operations, which includes our CMC, manufacturing, and quality functions. We look forward to further leveraging Ashita's expertise and talents as we pursue new markets and indications for support in Teflon and prepare to bring MT1621 to market. With that, I'll now hand the call over to Ashish for further commercial updates.